Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 5/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 10/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1707983 | 0.89 | CFTR (0.41) | CFTRIDH1ALDH1A1POLBRAB9A | |
| SCHEMBL1708092 | 0.88 | ALDH1A1 (0.39) | CFTRALDH1A1POLBRAB9ADHFR | |
| SCHEMBL1708248 | 0.86 | ALDH1A1 (0.39) | CFTRALDH1A1POLBRAB9ADHFR | |
| SCHEMBL1708670 | 0.85 | CYP2D6 (0.40) | CYP2D6ALOX5APKCNQ3KCNQ2DHFR | |
| SCHEMBL1707985 | 0.85 | CYP2D6 (0.38) | CYP2D6ALOX5APKCNQ3KCNQ2DHFR | |
| SCHEMBL1708079 | 0.77 | ALOX5AP (0.33) | CYP2D6ALOX5APIDH1 | |
| SCHEMBL10011833 | 0.76 | FFAR1 (0.39) | — | |
| SCHEMBL10291391 | 0.76 | FFAR1 (0.39) | — | |
| SCHEMBL1708037 | 0.75 | FFAR1 (0.33) | CYP2D6ALOX5APIDH1 | |
| SCHEMBL1708403 | 0.73 | ALDH1A1 (0.44) | ALDH1A1POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172351-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-05 | — | — | US | disclosed |
| EP-2440541-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010143733-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172351-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | GPR119, INSR, GLP1R | CYP2D6 4474/4885ALOX5AP 2982/4885CFTR 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.